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Abstract: Antivascular endothelial growth factor (anti-VEGF) therapies represent the standard 
of care for most patients presenting with neovascular (wet) age-related macular degeneration 
(neovascular AMD). Anti-VEGF drugs require repeated injections and impose a   considerable 
burden of care, and not all patients respond. Radiation targets the proliferating cells that cause 
neovascular AMD, including fibroblastic, inflammatory, and endothelial cells. Two new 
neovascular AMD radiation treatments are being investigated: epimacular brachytherapy and 
stereotactic radiosurgery. Epimacular brachytherapy uses beta radiation, delivered to the lesion 
via a pars plana vitrectomy. Stereotactic radiosurgery uses low voltage X-rays in overlapping 
beams, directed onto the lesion. Feasibility data for epimacular brachytherapy show a greatly 
reduced need for anti-VEGF therapy, with a mean vision gain of 8.9 ETDRS letters at 12 months. 
Pivotal trials are underway (MERLOT, CABERNET). Preliminary stereotactic radiosurgery data 
suggest a mean vision gain of 8 to 10 ETDRS letters at 12 months. A large randomized sham 
controlled stereotactic radiosurgery feasibility study is underway (CLH002), with pivotal trials to 
follow. While it is too early to conclude on the safety and efficacy of epimacular brachytherapy 
and stereotactic radiosurgery, preliminary results are positive, and these suggest that radiation 
offers a more durable therapeutic effect than intraocular injections.
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Introduction
Age-related macular degeneration (AMD) is the leading cause of blindness affecting 
adults over 50 years old in developed nations. In the UK, it accounts for almost 50% 
of those registered as blind or partially sighted, that is, between 182,000 and 300,000 
people.1 AMD occurs in 2 distinct groups: 90% is the ‘dry’ atrophic form and 10% 
is the ‘wet’ neovascular form. Although there are more incident cases of dry AMD 
than wet AMD, the latter accounts for 90% of patients with severe vision loss. The 
Royal National Institute for the Blind and the National Institute for Health and C  linical 
Excellence (NICE) have estimated that 26,000 new cases of neovascular AMD will be 
eligible for treatment per year in the UK alone.2
The characteristic feature of most cases of wet AMD is subfoveal choroidal 
  neovascularization (CNV). CNV is a process in which the vessels from the   choriocapillaris 
perforate Bruch’s membrane and enter the subretinal pigment epithelial and subretinal 
spaces. When these new CNV lesions leak or rupture, the accumulation of fluid and blood, 
together with the subsequent scarring, seriously impairs the photoreceptor layer.3Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Different techniques to treat or prevent neovascular 
AMD have been tried over the past few years with varying 
results. Until the recent introduction of antivascular endothe-
lial growth factor (anti-VEGF) medications, the management 
of AMD was based largely on reducing the decline in visual 
function. However, ranibizumab (Lucentis®; Novartis, Basel, 
Switzerland) has been shown to produce a significant visual 
gain in approximately a third of patients, with a mean gain 
of 7.2 letters in the group as a whole.4,5 These large studies 
required patients to have monthly intraocular injections, 
however, this represents an expensive and   burdensome 
course of treatment. Furthermore, when   treatment is reduced 
to an as-required regimen, as advised by NICE, the mean 
visual gain is approximately halved.6 There is therefore a 
need for a more durable treatment modality to reduce the 
cost and burden of treatment, while maintaining or improv-
ing vision.
Radiation and neovascular AMD
Certain biological principles suggest that radiation may be 
an effective treatment modality for wet AMD. This is based 
on the concept that the development of neovascular AMD 
is similar to a proliferative wound healing process, and that 
proliferating cells are known to be sensitive to the effects of 
radiation. Radiotherapy causes irreparable damage to DNA 
and protein synthesis, preventing further replication, while 
still maintaining cellular integrity. Although all cells in 
the area are affected, radiation has a selective effect, because 
nondividing cells are able to repair the damage to DNA, while 
rapidly proliferating cells discontinue the cell division cycle 
and undergo apoptosis.7
Radiation used for medical therapies can be divided into 
2 main categories depending on its method of delivery to 
the tissue. Brachytherapy uses a radiation source delivered 
directly to the lesion by surgery. The source is usually an 
isotope which produces ionizing radiation as it decays and 
emits energy. Teletherapy (external beam therapy) uses 
radiation formed into a beam which can be projected at an 
internal body tissue from an external source. The source can 
also be an isotope, but more recently electronically produced 
ionizing radiation has been used.8
Initial ophthalmology studies investigated external 
beam radiation to treat wet AMD. These used high energy 
radiation to penetrate the ocular and periocular tissue, and 
target the macula. While some studies showed results better 
than the natural history, the results do not compare favorably 
to those in the anti-VEGF era.9–11 This may be because of 
collateral damage to ocular tissue, and difficulty targeting 
macular lesions using technology that was designed for 
lesions that are usually several orders of magnitude larger. 
Another factor could have been the time-delay before radia-
tion has an effect. In the era before anti-VEGF therapy this 
meant the disease progressed before the benefit of radiation 
occurred. A disadvantage of early external beam therapy was 
that linear accelerators were used to generate the energy. 
These accelerators produce extremely high levels of energy 
which are tightly regulated and need special precautions to 
prevent escape of the radiation: usually lead-lined concrete 
walls, large power supplies, and cooling measures.12
Currently 2 different approaches to radiation therapy in 
the treatment of neovascular AMD are being investigated: 
epimacular brachytherapy (VIDION; NeoVista Inc. Fremont, 
CA) and stereotactic radiosurgery (IRay system; Oraya 
Therapeutics Inc. Newark, CA).
Synergistic effect
Anti-VEGF agents have a rapid onset of action but limited 
durability in many patients. In general, disease activity tends 
to recur as they are eliminated from the eye. By contrast, 
radiotherapy produces a delayed response but has a much 
longer duration of action. Therefore, there is good scientific 
rationale for a synergistic response when a combination 
approach is used, because both therapies target the disease 
in different ways.13 The anti-VEGF therapy inhibits growth 
f  actors in the local area while the radiotherapy disables the 
local inflammatory cell population and induces an apoptotic 
effect on the   vascular endothelium. The overall result from 
these 2 approaches has the potential to bring a faster and 
more   complete recovery of functional vision. This rationale 
is supported by experience from oncology, in which anti-
VEGF agents and radiotherapy were combined to treat colon 
cancer.14,15
Epimacular brachytherapy
introduction
Unlike previous attempts using external beam radiation, epi-
macular brachytherapy was developed to deliver intraocular 
radiation. Brachytherapy, from the Greek brachy, meaning 
‘short-distance’, places the source of radiation close to the 
CNV complex at the macula. In addition, this device uses 
beta radiation from a strontium-90/yttrium-90 source. Beta 
radiation has a rapid decline in dose with increasing dis-
tance from the source, which limits radiation exposure to a 
defined region, with little damage to adjacent normal tissue. Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
59
Radiation therapy for neovascular AMD
To date, no serious ocular or systemic complications have 
been reported in small uncontrolled clinical trials using a 
prototype device.16,17
Details of the procedure
The beta radiation used in epimacular brachytherapy is 
delivered via a pars plana vitrectomy, a well-established 
surgical procedure (Figures 1, 2, and 3). Once the vitreous 
has been removed the surgeon positions the probe over the 
CNV lesion. A preoperative fundus fluorescein angiogram is 
used to ensure that the area of maximum dosage is directed 
over the area of greatest disease activity. The probe is held in 
position for approximately four minutes and then removed. 
Surgery is usually undertaken using local anesthetic in a 
day case setting. Because beta radiation decreases with 
  increasing distance from the source, the delivery of radiation 
to neighboring structures is low. Hence the macular lesion 
receives 24 gray (Gy), the optic nerve receives 2.4 G, and 
the lens 0.00056 Gy.17
In the published trials of epimacular brachytherapy, 
patients received an anti-VEGF injection at the time of 
surgery and again 1 month later, to treat any pre-existing 
disease activity at the time of surgery. Thereafter they had 
anti-VEGF therapy as needed, based on disease activity.16,17
The potential risks of intraocular radiation include retin-
opathy, optic neuropathy, and cataract. The dose delivered to 
the macula is 24 Gy. The dose delivered to nearby structures 
during epimacular brachytherapy is below the reported safety 
threshold for each of these ocular structures (Table 1).17–22 The 
use of beta radiation also ensures that the total dose received 
by the patients is less than a routine chest X-ray.23
Epimacular brachytherapy is performed as part of a 
vitrectomy procedure and this combination of anti-VEGF 
therapy, vitrectomy, and radiation may be uniquely suited to 
the treatment of AMD. It has been proposed that the removal 
of the vitreous increases the level of oxygen available to 
the inner layers of the retina via diffusion from the aqueous 
humor.24–26 A reduced oxygen tension may play a role in 
the initial CNV formation. In addition, by increasing the 
oxygenation in the local area at the time of brachytherapy, 
it may increase the formation of free radicals and therefore 
the double-stranded DNA breaks required to prevent further 
CNV formation.27,28
Epimacular brachytherapy studies
Published trials
Two key preliminary studies provided the early data on the 
safety and efficacy of epimacular brachytherapy. The first 
(NVI-68) trial was a nonrandomized multicenter feasibility 
study with 34 treatment-naive subjects enrolled. Subjects 
received either 15 Gy (8 patients) or 24 Gy (26 patients) of 
beta radiation. Twelve months after treatment, no radiation-
related adverse events had been recorded. However, there was 
a significant difference in the visual acuity result between the 
2 groups, when tested using the ETDRS visual chart. In the 
24 Gy group, the mean change in visual acuity was a gain of 
10.3 letters (approximately 2 Snellen lines) while the 15 Gy 
group had a loss of -1.0 letters.16
The second (NV-111) trial was a prospective, nonran-
domized, multicenter study that enrolled 34 treatment-naive 
Figure 1 epimacular brachytherapy probe.
Figure 2 intraocular probe in mid vitreous cavity prior to placement on the retinal 
surface.
Figure 3 Probe positioned on the retinal surface.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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subjects. Subjects were treated with a single dose of 24 Gray 
epiretinal brachytherapy and two injections of anti-VEGF 
therapy, 1 at the time of surgery, and another 1 month later. 
Thereafter anti-VEGF therapy was administered as needed. 
Twelve months after treatment, there were no reported cases 
of radiation retinopathy. ETDRS visual acuity showed a 
mean improvement of 8.9 letters (approximately 2 Snellen 
lines), with 91% maintaining vision (,3 lines of vision 
loss/15 ETDRS letters) and 68% having stable or improved 
vision.17 Approximately three-quarters of patients required 
no further anti-VEGF therapy over the first year. By com-
parison, NICE anticipates patients would require 8 anti-
VEGF injections over this interval, if they were receiving 
ranibizumab monotherapy. These early   feasibility trials 
showed promising short-term results compared to anti-
VEGF therapy, and demonstrated the preliminary safety 
and efficacy of epimacular brachytherapy that prompted 
the larger ongoing studies.
Ongoing clinical trials
MeRiTAGe study
MERITAGE is a multicenter investigator-initiated study to 
evaluate the safety and efficacy of focal delivery of radiation 
in patients that require persistent injections of anti-VEGF 
therapy. This study was initiated in the UK and was sub-
sequently expanded to include 5 international sites in the 
United States and Israel. A total of 53 participants have now 
completed 12 months of follow-up, and results are expected 
to be published shortly.
CABeRNeT study
CABERNET is a commercial, multinational, pivotal ran-
domized controlled trial evaluating the safety and efficacy 
of   epimacular brachytherapy in treatment-naive patients. 
This study has now completed recruitment, having enrolled 
495   subjects across 17 sites. Results will be released when 
patients reach 24 months follow-up, and are expected in 
late 2011.
MeRLOT study
MERLOT is a noncommercial, investigator-initiated, UK 
  multicenter randomized controlled trial in patients who 
have already commenced anti-VEGF therapy. It is has been 
adopted on to the National Institute of Health Research 
(NIHR) Comprehensive Clinical Research Network (CCRN) 
portfolio, an organization that provides assistance to studies 
addressing areas of importance to the National Health Ser-
vice (NHS). MERLOT is actively recruiting at 16 UK NHS 
hospitals with further sites to join soon. In total 363 patients 
will be randomized in a 2:1 ratio, comparing epimacular 
brachytherapy and as required ranibizumab, to ranibizumab 
monotherapy.
Whereas most studies of epimacular brachytherapy 
target patients who have not yet commenced any   treatment, 
  MERITAGE and MERLOT both target those who are 
  requiring regular eye injections. The rationale is that there 
are limited surgical resources and these resources are best 
directed to those who have not fully responded to ranibi-
zumab therapy, or whose response is short-lived. These 
patients have the most to gain from a therapy that may reduce 
their frequency of anti-VEGF retreatment.
Stereotactic radiosurgery
introduction
More recently investigators have revisited external beam 
therapy, using a technique called stereotactic radiotherapy 
or radiosurgery. This treatment directs beams from differ-
ent angles relative to the target area, thereby minimizing the 
exposure to surrounding healthy tissue, and at the same time 
precisely targeting the radiation energy onto the lesion. The 
IRay system uses a low voltage X-ray source that does not 
require the same degree of radiation shielding as the early 
linear a  ccelerators. The system is designed to overcome 
the t  raditional d  isadvantages of external beam therapy by 
d  ividing the dose into several   separate beams that pass 
into the eye via different locations on the sclera. An added 
benefit is the use of the lower energy X-ray source allowing 
Table 1 Clinically observable radiation damage thresholds for ocular structures and the calculated doses for epimacular brachytherapy 
and stereotactic radiosurgery17–22
Tissue Effect Reported thresholds for clinically  
observable radiation damage
Dose delivered during  
epimacular brachytherapy
Dose delivered during  
stereotactic radiosurgery
Lens Cataract 2 Gy 0.00056 Gy 0.12–0.13 Gy
Retina Radiation retinopathy 35–55 Gy  24 Gy 16–24 Gy
Optic nerve Optic neuropathy .55 Gy 2.4 Gy 0.2–0.37 Gy
Abbreviation: Gy, gray.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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treatment within the clinical environment, without expensive 
safety precautions.21,29
Details of the procedure
The radiation source uses a robotically controlled delivery 
system connected to the patient using a contact lens and 
25 mmHg suction (Figure 4). The system is designed to fit 
in a standard clinical environment and runs off a 220- to 
240-V wall socket, without the need for room shielding. 
It delivers two to three separate beams through the inferior 
pars plana region of the sclera (5-, 6- and 7-o’clock) to 
overlap on the predicted foveal center, therefore dispersing 
the scleral entry dose and minimizing exposure of the lens 
and optic nerve30 (Figure 5). The patient is secured in posi-
tion with a head restraint that also contains a lead backing 
to prevent radiation traveling beyond the patient. Exposure 
to the lower lid is avoided by a lid retractor. The operator is 
separated from the patient during treatment via a lead-lined 
glass shield, which allows the operator to monitor the patient 
(Figure 6). 21,29 The patient’s eye is then secured in position 
with a vacuum-coupled contact lens interface with suction; 
the system can detect any eye motion and stabilizes the eye 
during treatment. The eye is then continually tracked during 
treatment and an inbuilt safety feature interrupts the radiation 
treatment if the eye moves out of position.
Stereotactic radiosurgery studies
CLH001
CLH001 was a single-center uncontrolled pilot study that 
included 62 participants with neovascular AMD. The study 
included patients who had already received anti-VEGF 
therapy, and others who were treatment naïve. It investigated 
2 radiation doses (16 Gy and 24 Gy) and different induction 
treatment regimens. Induction involved anti-VEGF therapy 
at baseline and month 1 with the radiotherapy in between, 
or radiotherapy only at baseline. All the regimens then 
administered anti-VEGF as required. At 12 months visual 
acuity had stabilized or improved for the majority of 
patients, and the mean gain has been 8 to 10 ETDRS letters 
(approximately 2 Snellen lines) (the 12-month data were 
presented by Peter Kaiser at Angiogenesis Feb 20, 2010 
and again by Darius Moshfeghi at Macula Society Feb 
24–27, 2010).
Ongoing clinical trials
CLH002 study
CLH002 is a commercial, multinational, randomized controlled 
feasibility study evaluating the safety and effectiveness of 
low voltage stereotactic radiosurgery in patients who have 
previously been treated with anti-VEGF therapy. CLH002 is 
actively recruiting at more than 20 hospitals in five countries. 
In total, 210 patients will be randomized to 16 Gy, 24 Gy, or 
sham stereotactic radiosurgery, with as required ranibizumab 
in all groups.
Figure 4 The robotically controlled system connected to the patient via a contact lens.
Figure 5 illustration of the trajectory of the external beam radiation through the 
pars plana into the macula, avoiding the lens and optic nerve.
Figure 6 The iRay system set up within the clinical environment with the operator 
controls separated by the lead-lined glass screen.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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CLH003 study
CLH003 is a multinational pivotal RCT, planned to start 
in 2011.
Conclusion
The ongoing management of patients with wet AMD 
r  epresents a considerable challenge to eye departments across 
the country. The ideal treatment for this sight-threatening 
condition would maintain or improve a patient’s vision, 
whilst limiting the number of treatment follow-ups. The 
introduction of anti-VEGF therapy represents an important 
advance in treatment. However, patients require frequent hos-
pital review, and most require regular intravitreal injections 
to maintain the benefit. This course of treatment imposes a 
considerable burden for affected older adults, and their car-
ers. In addition the injections may elicit patient anxiety and 
discomfort, and there is a cumulative risk of complications 
such as endophthalmitis and retinal detachment.
Both epimacular brachytherapy and stereotactic radiosur-
gery have the potential to significantly improve the quality 
of life for patients suffering with wet AMD, by reducing 
their reliance on frequent injections and therefore the need 
for such regular long-term follow-up.
If the results of the early studies are replicated in large 
RCTs, then these radiotherapy treatments could offer a useful 
alternative for those patients whose response to anti-VEGF 
therapy is incomplete or short-lived. It is however important 
that these new treatments are thoroughly assessed with long-
term follow-up and robust analysis of large clinical trials. In 
particular, any reduction in demand for anti-VEGF treatment 
needs to occur in the context of an acceptable visual outcome, 
and a favorable safety profile.
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